TICKERNERD
Menu
CGTXCGTXHealthcare · Biotechnology

CGTX Stock Forecast: Cognition Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$0.74
−1.28% on the day

The 3 Wall Street analysts covering Cognition Therapeutics, Inc. hold a median 12-month price target of $3 — +305.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$71.2M
Ticker Nerd rank
34/ 100
Median analyst target
$3.00
Analysts covering
3
Revenue$0.0
Operating income−$4.2M
Net income−$3.9M
Free cash flow−$3.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.5%
1M
−22.5%
YTD
−45.2%
1Y
−53.2%
From 52W high
−58.9%
From 52W low
+24.3%
$0.60
$1.80
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CGTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cognition Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
34/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
81
Size
77
Revisions
65
Quality
38
Value
33
Accruals
29
Momentum
24
Issuance
22
Volatility
9

Growth (81): Sales and profits are climbing, and climbing faster than before.

Volatility (9): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CGTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26CGTXHigh $4.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $3.00Median $3.00High $4.00

The green dot is the last close — the median target sits +305.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Mar 2026Chardan CapitalMaintainsBuy$4.00
4 Dec 2025HC Wainwright & Co.ReiteratesBuy—
21 Nov 2025B. Riley SecuritiesReiteratesBuy—
19 Nov 2025HC Wainwright & Co.ReiteratesBuy—
8 Aug 2025Chardan CapitalMaintainsBuy—
26 June 2025HC Wainwright & Co.ReiteratesBuy—
27 May 2025HC Wainwright & Co.MaintainsBuy—
8 May 2025Chardan CapitalMaintainsBuy—
24 Mar 2025HC Wainwright & Co.MaintainsBuy—
21 Mar 2025Chardan CapitalMaintainsBuy—
26 Feb 2025Chardan CapitalMaintainsBuy—
19 Dec 2024B. Riley SecuritiesUpgradeBuy—
19 Dec 2024Chardan CapitalMaintainsBuy—
19 Dec 2024HC Wainwright & Co.MaintainsBuy—
27 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024Chardan CapitalMaintainsBuy—
4 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024Chardan CapitalMaintainsBuy—
12 Aug 2024HC Wainwright & Co.MaintainsBuy—
6 Aug 2024B. Riley SecuritiesDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CGTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CGTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Cognition Therapeutics, Inc. returned −53.2% against +13.6% for the S&P 500, dividends included.

CGTX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26CGTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CGTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Cognition Therapeutics, Inc. (CGTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.4×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
2.2×

Cheaper than 40% of US stocks

EV / EBITDA
−1.0×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−83.8%

Higher than 15% of US stocks

Return on assets
−78.2%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cognition Therapeutics, Inc. (CGTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cognition Therapeutics, Inc. has a market value of $71.2M and an enterprise value of $37.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$16.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$17.7M.

  • Shares outstanding: 95.1M.

  • Trailing P/E: −2.4×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cognition Therapeutics, Inc. employs 14 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

CGTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGTXCognition Therapeutics, Inc.$71.2M34
NMRANeumora Therapeutics, Inc.$71.6M33
MAIAMAIA Biotechnology, Inc.$70.4M27
TENXTenax Therapeutics, Inc.$70.4M18
MNOVMediciNova, Inc.$72.2M97
CRDFCardiff Oncology, Inc.$69.2M48
TELOTelomir Pharmaceuticals, Inc.$74.4M30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cognition Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CGTX news & analysis

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

GlobeNewsWire · 22 Oct 2026positive

Cognition Therapeutics announced that it aligned with the FDA on key elements of a Phase 3 study of zervimesine (CT1812) in dementia with Lewy bodies, including patient selection, dose, duration, and endpoints.

Why it matters — The FDA alignment provides CGTX watchers information about the planned design of the pivotal Phase 3 study.

Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045

GlobeNewsWire · 13 Oct 2026positive

Cognition Therapeutics announced issuance of a composition-of-matter patent for zervimesine (CT1812), extending protection through 2045. The excerpt says an additional five years of patent protection may be possible through a standard extension.

Why it matters — The patent issuance and potential extension are relevant to CGTX watchers tracking the duration of intellectual-property protection for zervimesine.

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

GlobeNewsWire · 29 Sept 2026neutral

Cognition Therapeutics has scheduled a Type C meeting with the FDA's Division of Neurology for October 20th to align on endpoints for the Phase 3 trial of Zervimesine (CT1812) in dementia with Lewy bodies (DLB). The meeting is expected to define the endpoint for the Phase 3 study.

Why it matters — A CGTX watcher would care because the FDA meeting outcome will shape the design and endpoint of the company's Phase 3 trial for Zervimesine in DLB, a key step in its clinical development.

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Cognition Therapeutics announced that its president and CEO, Lisa Ricciardi, intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. During the presentation, she will discuss progress on the company's development of zervimesine for Alzheimer's disease and dementia with Lewy bodies.

Why it matters — A CGTX watcher would care because the CEO's presentation offers an opportunity to hear direct updates on the clinical development of the company's lead candidate, zervimesine.

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 7 Aug 2026positive

Cognition Therapeutics (CGTX) reported a second-quarter loss of $0.04 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from the $0.11 per-share loss a year earlier.

Why it matters — A CGTX watcher would care because the narrower-than-expected loss shows the company beat analyst estimates and improved its bottom line versus the same quarter last year.

FAQ

Frequently asked questions about CGTX stock

What is the CGTX stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Cognition Therapeutics, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGTX stock a buy right now?

Of the 3 analysts covering Cognition Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cognition Therapeutics, Inc. 34 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGTX?

As at 28 Oct 2026, Cognition Therapeutics, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (81 of 100).

Will CGTX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +305.7% from the last close, and Ticker Nerd's factor model ranks Cognition Therapeutics, Inc. 34 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGTX stock forecast for 2030?

No analyst covering Cognition Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.

How has CGTX stock performed over the past year?

Cognition Therapeutics, Inc. returned -53.2% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cognition Therapeutics, Inc. do?

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for age-related degenerative diseases affecting the central nervous system and the retina.

What is the latest news on CGTX?

The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies". Cognition Therapeutics announced that it aligned with the FDA on key elements of a Phase 3 study of zervimesine (CT1812) in dementia with Lewy bodies, including patient selection, dose, duration, and endpoints.

Company

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for age-related degenerative diseases affecting the central nervous system and the retina. Its lead program centers on zervimesine (CT1812), an oral candidate designed to protect neuronal synapses and modulate disease-related protein interactions. The company is evaluating this candidate across multiple neuroscience and neuro-ophthalmology settings, including Alzheimer’s disease, mild cognitive impairment, dementia with Lewy bodies, and geographic atrophy associated with dry age-related macular degeneration. Cognition Therapeutics combines mechanistic research with translational and clinical development to address disorders linked to synaptic dysfunction and cellular stress. Headquartered in Purchase, New York, the company plays a specialized role in the biotech market as a developer of targeted treatments for complex neurodegenerative and retinal conditions.

CEO Ms. Lisa Ricciardi · 14 employees · United States · https://www.cogrx.com